Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis

References

• WolchokJDPD-1 BlockersCell2015162593726317459
   PubMed Web of Science ®Google Scholar
• LeachDRKrummelMFAllisonJPEnhancement of antitumor immunity by CTLA-4 blockadeScience19962715256173417368596936
   PubMed Web of Science ®Google Scholar
• ReckMBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnn Oncol2013241758322858559
   PubMed Web of Science ®Google Scholar
• BeerTMKwonEDDrakeCGRandomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic Chemotherapy-Naive castration-resistant prostate cancerJ Clin Oncol2017351404728034081
   PubMed Web of Science ®Google Scholar
• GovindanRSzczesnaAAhnMJPhase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancerJ Clin Oncol201735303449345728854067
   PubMed Web of Science ®Google Scholar
• LynchTJBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyJ Clin Oncol201230172046205422547592
   PubMed Web of Science ®Google Scholar
• EggermontAMChiarion-SileniVGrobJJAdjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialLancet Oncol201516552253025840693
   PubMed Web of Science ®Google Scholar
• KwonEDDrakeCGScherHIIpilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialLancet Oncol201415770071224831977
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcdermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• LarkinJChiarion-SileniVGonzalezRCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med20153731233426027431
   PubMed Web of Science ®Google Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• KangYKBokuNSatohTNivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet2017390101112461247128993052
   PubMed Web of Science ®Google Scholar
• LangerCJGadgeelSMBorghaeiHCarboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyLancet Oncol201617111497150827745820
   PubMed Web of Science ®Google Scholar
• PostowMAChesneyJPavlickACNivolumab and ipilimumab versus ipilimumab in untreated melanomaN Engl J Med2015372212006201725891304
   PubMed Web of Science ®Google Scholar
• TopalianSLDrakeCGPardollDMImmune checkpoint blockade: a common denominator approach to cancer therapyCancer Cell201527445046125858804
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• WaterhousePPenningerJMTimmsELymphoproliferative disorders with early lethality in mice deficient in CTLA-4Science199527052389859887481803
   PubMed Web of Science ®Google Scholar
• NishimuraHOkazakiTTanakaYAutoimmune dilated cardio-myopathy in PD-1 receptor-deficient miceScience2001291550231932211209085
   PubMed Web of Science ®Google Scholar
• MichotJMBigenwaldCChampiatSImmune-related adverse events with immune checkpoint blockade: a comprehensive reviewEur J Cancer20165413914826765102
   PubMed Web of Science ®Google Scholar
• LazarouJPomeranzBHCoreyPNIncidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studiesJAMA199827915120012059555760
   PubMed Web of Science ®Google Scholar
• BuchbinderEIDesaiACTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibitionAm J Clin Oncol20163919810626558876
   PubMed Web of Science ®Google Scholar
• FifeBTBluestoneJAControl of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathwaysImmunol Rev200822416618218759926
   PubMed Web of Science ®Google Scholar
• ParryRVChemnitzJMFrauwirthKACTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanismsMol Cell Biol200525219543955316227604
   PubMed Web of Science ®Google Scholar
• PuzanovIDiabAAbdallahKManaging toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working GroupJ Immunother Cancer2017519529162153
   PubMed Web of Science ®Google Scholar
• ThompsonJANew NCCN guidelines: recognition and management of Immunotherapy-Related toxicityJ Natl Compr Canc Netw2018165S59459629784734
   PubMed Web of Science ®Google Scholar
• El OstaBHuFSadekRChintalapallyRTangSCNot all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trialsCrit Rev Oncol Hematol201711911229065979
   PubMed Web of Science ®Google Scholar
• WangDYYeFZhaoSJohnsonDBIncidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysisOncoimmunology2017610e134480529123955
   PubMed Web of Science ®Google Scholar
• NishinoMShollLMHodiFSHatabuHRamaiyaNHAnti-PD-1-Related pneumonitis during cancer immunotherapyN Engl J Med2015373328829026176400
   PubMed Web of Science ®Google Scholar
• ThompsonJANew NCCN guidelines: recognition and management of immunotherapy-related toxicityJ Natl Compr Canc Netw2018165S59459629784734
   PubMed Web of Science ®Google Scholar
• O’DaySJMaioMChiarion-SileniVEfficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnn Oncol20102181712171720147741
   PubMed Web of Science ®Google Scholar
• WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
   PubMed Web of Science ®Google Scholar
• TopalianSLSznolMMcDermottDFSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabJ Clin Oncol201432101020103024590637
   PubMed Web of Science ®Google Scholar
• WeberJSKudchadkarRRYuBSafety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanomaJ Clin Oncol201331344311431824145345
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar